Physician profile
Kit D Kuss
NPI 1902877756
$9,173.22
in general payments reported to CMS, 2019-2025
46 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,278 · 2020: $1,446 · 2021: $1,919 · 2022: $1,111 · 2023: $1,288 · 2024: $1,092 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,419.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $941.89 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $821.03 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $783.44 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $660.61 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $588.66 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $518.74 | 2019-2025 | Repatha, Otezla, Otezla |
| Teva Pharmaceuticals USA, INC. | $478.34 | 2019-2023 | Austedo |
| Jazz Pharmaceuticals INC. | $461.89 | 2019-2025 | Xywav |
| Merck Sharp & Dohme LLC | $326.13 | 2019-2024 | Verquvo, Belsomra |
| Pfizer INC. | $313.95 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.10 | 2020-2022 | |
| Eisai INC. | $236.43 | 2020-2025 | |
| Abbvie INC. | $225.75 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.12 | 2019-2025 | Xifaxan, Trulance |
| Kowa Pharmaceuticals America, INC. | $176.44 | 2019-2025 | Livalo, Seglentis, Zoryve |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kit Kuss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.